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Gag Gal ’, A. Arxu Sayiner’, Ceyhun O x y u r t  I ,  Ibrahim Ciireklibatirl, Tijen Oxacar2 
and Ziihre Badak2 
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Objective: To investigate the effectiveness of ciprofloxacin in the treatment of chronic bacterial prostatitis due to  
various microorganisms. 
Methods: Patients with chronic prostatitis symptoms were evaluated by culture of their expressed prostatic secretion 
and fractionated urine samples according to the four-glass localization test of Meares and Stamey. Patients with an 
isolated microbial agent were treated with ciprofloxacin 500 mg  twice a day for 4 weeks and re-evaluated 1 week and 6 
months after the treatment. 
Results: Sixteen of the 68 (23.5%) evaluated patients were diagnosed as having chronic prostatitis with an isolated 
microbial agent. Ureaplasma urealyticum was the most common microorganism related to chronic prostatitis. 
Eradication of the previously isolated microbial agent was found in 11 of the 16 patients at the first-week evaluation. At 
the 6-month control evaluation no growth was observed on the cultures of seven of the 16 (43.8%) patients, which was 
accepted as successful treatment. 
Conclusions: U. urealyticum can be the responsible agent in some chronic prostatitis patients. Ciprofloxacin may be 
a treatment option in chronic prostatitis. 
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INTRODUCTION 
Although chronic prostatitis is a common problem in 
urology, its etiology, diagnosis and treatment are not 
yet clear [l]. For this reason, chronic prostatitis is a 
troublesome disease for both the patients and the 
physicians. The diagnosis cannot be made simply with 
the patient’s history and physical examination. The 
prostate is commonly normal on digital rectal examina- 
tion and there are usually no diagnostic findings in 
the intravenous urogram or cystoscopy. Although a 
response can initially be obtained with antibiotic 
treatment, recurrence with the same or a different 
microorganism is seen in a short time in most cases. 
Ciprofloxacin is a fluoroquinolone and acts by 
inhibition of bacterial DNA gyrase. Its antibacterial 
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spectrum includes Gram-negative bacteria which com- 
monly cause bacterial prostatitis [2]. Following oral 
administration, its concentrations in the ejaculate and 
in the seminal fluid are several-fold higher than that in 
the serum [3]. It penetrates into the prostatic tissue, 
and exceeds the MIC9o level for members of the 
Enterobacteriaceae [3]. O n  the basis of these data, we 
investigated the effectiveness of ciprofloxacin in the 
treatment of bacterial prostatitis due to various micro- 
organisms. 
PATIENTS A N D  METHODS 
In total, 68 male patients with symptoms suggesting 
chronic prostatitis were evaluated. Patients who had 
received antibiotics in the preceding 30 days were 
excluded from the study. The four-glass localization 
test of Meares and Stamey was used for the diagnosis 
of prostatic infection [4]. First-voided urine samples 
(VBl), mid-stream urine specimens (VE32), postprostatic 
massage urine specimens (VB3) and expressed pro- 
static secretions (EPS) were collected, microscopically 
examined and quantitatively cultured for the common 
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aerobic bacteria Ureaplasrna urealyticurn and Mycoplasrna 
horninis. The microbial isolate was accepted as the 
etiologic agent of the prostatitis when a growth of 
> lo4  CFU/mL was found in EPS and/or 2103 
CFU/mL in VB3 and at least a 10-fold higher level 
of growth in VB3 compared to VB1 and VB2. 
Leukocyte counts were considered significant when 
210 leukocytes/high-power field in a smear of EPS 
and/or in the sediment of centrifuged VB3 were 
detected in a patient with leukocyte-free VB2 [S]. In 
addition, EPS and/or VB3 sediments were tested for 
Chlamydia trachornatis antigen by an enzyme-linked 
immunoassay test (Vidas, BioMtrieux). Antibiotic 
sensitivity tests on the aerobic bacteria were done by 
the disk diffusion method. Patients with non-bacterial 
prostatitis and prostadynia were not included in the 
antibiotic treatment program. Patients in whom a 
microbial origin was determined were treated with 
SO0 mg of ciprofloxacin twice a day for 4 weeks. All 
the patients were re-evaluated with the same method 1 
week and 6 months after the treatment. The treatment 
was considered successful when a negative culture was 
obtained in VB3 and EPS samples. 
O f  the 68 patients evaluated, 16 (23.5%) were diag- 
nosed as having chronic prostatitis with an isolated 
microbial agent. Based on the criteria described above, 
the causative agents were U. icrealyticurn in 11 cases 
(68.75%), Escherichia coli in two cases (12.S%), and 
M.  horninis, Entevococcus faecalis and Staphylococcus auveus 
each in one case. One week ;ifier the ciprofloxacin 
treatment, patients were re-evahated. The previously 
isolated microbial agent was found to be eradicated in 
11 of the 16 patients (eight with U uvealyticurn, two 
with E.  coli and one with Enterococcus faecalis). The 
treatment was not successful in three patients infected 
with U. urealyticurn and one infected with S. aureus. 
Their medication was therefore changed and the 6- 
month follow-up cultures wert: not performed. The 
case with M .  horninis required a second 4-week course, 
and finally a negative culture was obtained. At the 6- 
month control evaluation of the treated group, the 
initial microbial agents were isolated again from four 
patients (two U. urealyticurn and two E. coli) although 
symptoms had subsided. Since subspecies typing was 
not performed on the isolates, it was not possible to 
differentiate relapse from reinfection. One of the 
two re-isolated E. coli strains was found to be resistant 
to ciprofloxacin at the 6-month control evaluation, 
although no resistance was observed initially. Results 
obtained before and after treatm.ent are summarized in 
Table 1. Overall, disappearance of the microbial agent 
and decrease in the severity of the initial symptoms 
were found in 7 of 16 (43.8%) patients, at the 6- non nth 
control evaluation. There were no side-effects necessi- 
tating interruption of the treatment in the study group. 
Table 1 Findings of the localization studies before and after the treatment 
After treatment" 
Patient no. Before treatment' 
First week 
Agent/WBC count 
Sixth month 
Agent/WBC count 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
U irrealyficum 
U. urealyticum 
(1 urealyticum 
U. urealyticirm 
U. urealyticum 
U urealyticum 
U. urealyticrrm 
U. urealyticurn 
U. urealyticum 
U urealyficum 
U. urealyticum 
E. coli 
E .  coli 
S. uureus 
Errterococcus fuecalis 
M. horninis 
U. urealyticum/? 
N G / f  
NG/- 
U mealyticum/+ 
NG/+ 
NG/+ 
NG/- 
U. urealyticum/f 
NG/- 
NG/- 
NG/+ 
NG/? 
NG/- 
S. aweus/+ 
NG/+ 
M.  horninis/?' 
NLI 
U urealytici4m/+ 
NG/- 
ND 
NG/+ 
NG/ f  
NG/- 
NL) 
11. urealyticuwi/f 
NG/? 
NG/- 
E. coli/? 
E. coli/? 
ND 
N G / f  
NG/f  
'All the patients had >10/high-power field (hpf) leukocytes in EPS and/or VB3 specimens. 
"NG: no  growth in EPS and/or VB3 cultures. Leukocyte counts m EPS samples: +, >lO/hpi; +, 5-9/hpf; -, <5/hpf. ND: Not done 
because of therapy change after the first-week control. 
'Successful result achieved after the repeat of the treatment. 
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DISCUSSION 
The members of the Enterobacteriaceae, enterococci 
and Pseudomonas spp. are cited as the common causative 
pathogens in prostatitis in different studies [6,7]. There 
are conflicting data concerning the role of genital 
mycoplasmas and Ctvuckomatis in the etiology of 
chronic prostatitis [5,6]. The localization of infection 
with the quantitative culture method is required 
because of the presence of U. urealyticum and M.  hominis 
in normal urethral flora [5]. In our investigation, 
U. uvealyticum was the most common and E. coli was the 
second commonest microorganism related to chronic 
prostatitis. The importance of U. uvealyticurn in the 
chronic prostatitis group has also been emphasized 
in other studies [5,7,8]. Our study also indicates that 
U. urealyticum cultures should be included in the micro- 
biological evaluation of chronic prostatitis. 
There is no consensus concerning the treatment of 
patients with chronic bacterial prostatitis. Although co- 
trimoxazole has been accepted as an effective drug 
for years, its clinical efficacy was found to be only 30% 
[9]. The results with doxycycline and minocycline 
were also unsatisfactory [9]. The increasing tetracycline 
resistance among several microorganisms, including 
genital niycoplasmas, is another problem of this treat- 
ment. The search for an effective therapeutic agent 
has included the investigation of quinolones [7,10]. 
Differences between study groups, treatments and 
follow-up schedules do not allow us to reach a general 
conclusion. In a retrospective study where the overall 
cure rate was 23.896, 110 significant differences in 
efficacy were found between tetracycline, quinolone 
and co-trimoxazole [6]. However, in different cipro- 
floxacin studies, successful results were obtained at the 
6-nionth, first-year and 30-month follow-up in up to 
64% of the cases [7,10,11]. In these studies, however, 
the main causative agents were members of the 
Enterobacteriaceae. In our investigation, antimicrobial 
susceptibility tests were not done for mycoplasmas but 
ciprofloxacin is reported to have a wide range of 
minimum inhibitory concentration (MIC) values for 
U. urealyticunz isolates, between 0.5 and 16 pg/niL, and 
for M .  hominis between 0.1 and 1 pg/mL [12,13]. It is 
also reported that an alkaline environment enhances the 
activity of fluoroquinolones [9,10]. The alkaline pH of 
the prostatic fluid in prostatic infections may partially 
explain the therapeutic success in this study [lO]. 
In conclusion, our results suggest that U. urealyticuin 
can be the responsible agent in some chronic prostatitis 
patients and that ciprofloxacin can be a treatment 
option. Since the patients with unsuccessful treatment 
in our study were not followed up, further controlled 
studies are required to confirm the action of cipro- 
floxacin against U. uvealyticum. The follow-up showed 
the need for long-term control of chronic prostatitis 
patients after treatment, since the initial microbial 
agents were isolated from four patients after 6 months. 
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